AstraZeneca PLC (AZNCF)
| Market Cap | 283.73B |
| Revenue (ttm) | 58.13B |
| Net Income (ttm) | 9.40B |
| Shares Out | n/a |
| EPS (ttm) | 6.02 |
| PE Ratio | 30.19 |
| Forward PE | 18.11 |
| Dividend | 3.13 (1.70%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,737 |
| Average Volume | 1,347 |
| Open | 184.00 |
| Previous Close | 183.74 |
| Day's Range | 180.35 - 184.00 |
| 52-Week Range | 122.26 - 188.50 |
| Beta | 0.17 |
| RSI | 57.52 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
BREAKING: Trump strikes major deal with UK on drug pricing
FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca Shares Soar 7% as Pharma Giant Unveils Breakthrough Cancer Drug Data
Anglo-Swedish pharmaceutical giant AstraZeneca has made investors jump with record-breaking trial outcomes of its next-generation lung cancer treatment, and its shares shot up by 7% on the London Stoc...
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from ...
AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers
FDA approves AstraZeneca's Imfinzi plus FLOT for ... Full story available on Benzinga.com
AstraZeneca (AZN) Gains U.S. Approval for Imfinzi in Cancer Treatment
AstraZeneca (AZN) Gains U.S. Approval for Imfinzi in Cancer Treatment
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resulting in substantial annual savings on presc...
AstraZeneca Announces Approval Of Imfinzi In The US
(RTTNews) - AstraZeneca (AZN, AZN.L) said its Imfinzi, or durvalumab, in combination with standard-of-care FLOT chemotherapy has been approved in the US for the treatment of adult patients with resect...
AstraZeneca (AZN) Gains FDA Approval for Expanded Use of Imfinzi
AstraZeneca (AZN) Gains FDA Approval for Expanded Use of Imfinzi
AstraZeneca's Imfinzi granted approval for gastric cancers
AstraZeneca (AZN) Gains U.S. Nod for Imfinzi in Gastric Cancer Treatment
AstraZeneca (AZN) Gains U.S. Nod for Imfinzi in Gastric Cancer Treatment
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025. • AZN is in...
AstraZeneca Shares Leap 9% as Pharma Giant Secures Breakthrough Cancer Drug Approval in UK Market
Anglo-Swedish pharmaceutical giant AstraZeneca plc sparked a frenzy in healthcare shares today, with shares soaring more than 9% to 12,500 pence on the London Stock Exchange after the regulators gave ...
AstraZeneca (AZN) and Harbour BioMed Enhance Biotherapeutics Partnership
AstraZeneca (AZN) and Harbour BioMed Enhance Biotherapeutics Partnership
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discover...
AstraZeneca To Invest $2 Billion In Maryland Manufacturing Expansion
(RTTNews) - AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing presence in Maryland. The investment includes a major expansion of the company's flagship biologi...
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more.
Why AstraZeneca Stock Bumped Higher Today
The company is wasting little time figuring out the particulars of a sweeping capital investment program.
AstraZeneca (AZN) to Invest $2B in U.S. Production Expansion
AstraZeneca (AZN) to Invest $2B in U.S. Production Expansion
AstraZeneca expands U.S. production footprint with $2B investment in Maryland
AstraZeneca (AZN) Plans $2 Billion Expansion in Maryland
AstraZeneca (AZN) Plans $2 Billion Expansion in Maryland